Aclaris Therapeutics (ACRS) Total Current Liabilities (2017 - 2025)
Historic Total Current Liabilities for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $25.6 million.
- Aclaris Therapeutics' Total Current Liabilities rose 3621.92% to $25.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.6 million, marking a year-over-year increase of 3621.92%. This contributed to the annual value of $31.6 million for FY2024, which is 208.06% up from last year.
- As of Q3 2025, Aclaris Therapeutics' Total Current Liabilities stood at $25.6 million, which was up 3621.92% from $26.8 million recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' Total Current Liabilities ranged from a high of $31.6 million in Q4 2024 and a low of $14.5 million during Q1 2021
- Its 5-year average for Total Current Liabilities is $21.3 million, with a median of $20.1 million in 2024.
- Its Total Current Liabilities has fluctuated over the past 5 years, first crashed by 3130.67% in 2024, then skyrocketed by 7114.53% in 2025.
- Quarter analysis of 5 years shows Aclaris Therapeutics' Total Current Liabilities stood at $22.9 million in 2021, then dropped by 4.33% to $21.9 million in 2022, then soared by 41.09% to $31.0 million in 2023, then increased by 2.08% to $31.6 million in 2024, then fell by 18.88% to $25.6 million in 2025.
- Its Total Current Liabilities was $25.6 million in Q3 2025, compared to $26.8 million in Q2 2025 and $21.5 million in Q1 2025.